STENOCARE Executive team to exercise TO1 Warrants
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (Stenocare) is currently offering new shares at a discounted rate of DKK 2.11 for TO1 Warrant owners and, through the acquisition of Warrants, new investors. Today, members of the Stenocare Executive Team have committed to exercise their TO1 Warrants thus acquiring 6% of the new shares in this transaction.
The offer: Stenocare completed a Share Issue in June 2023 that was subscribed with 127%. The participants also received additional rights to purchase more Stenocare shares at a discounted price during December 2023 and June 2024. These rights are called “TO1 Warrants” and ”TO2 Warrants”, and between December 6-19 one TO1 Warrant gives the holder a right to buy one new Stenocare shares at an discounted price of DKK 2.11 per share.
Participants from management: Key members of the Stenocare Executive Team have decided to exercise their TO1 Warrants. It is the Chairman of the Board, the CEO, CFO and co-founder Steno Group that participate. Their total exercise is for 109.195 shares, which is 6% of total new shares being offered.
Opportunity for all to purchase additional Stenocare shares: It is possible for both current owners of TO1 Warrants and new investors to subscribe (ie purchase) additional new Stenocare shares at DKK 2.11 through the acquisition of TO1 Warrants. Holders of existing TO1 warrants use these to buy the new shares at DKK 2.11/each and/or buy additional TO1 warrants which can then be used (exercised) to buy new shares DKK 2.11/each. Anyone can buy TO1 Warrants under the ticker “STENO TO 1”, and then exercise these for the purchase of new Stenocare shares. Please notice that last day for purchasing TO1 Warrants is December 15, and last day for exercising the TO1 Warrants is December 19.
CEO of Stenocare, Thomas Skovlund Schnegelsberg, comments: "The Executive Team is excited with the progress for Stenocare and the outlook for the coming quarters and years. We welcome investors to join our warrant transaction and become part of our shareholder community of approx. 7000 members”.
For more information about the TO1 Warrant transaction and the Stenocare business case: https://stenocare.com/share-issue-to1-2023/
Sign-up for Stenocare news here: https://stenocare.com/subscribe-for-newsletter/ to automatically receive the latest news and information about the company.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.
www.stenocare.com www.stenocare.dk